5 terminated. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 3 | Terminated 3 |
Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity Defibrotide - DLBCL, Neurotoxicity Syndromes | Phase 2 | Terminated | Jazz Pharmaceuticals | 25 | 2019-10-04 | 2021-12-09 |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma imvotamab - Non-Hodgkin Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | IGM Biosciences, Inc. | 97 | 2019-09-30 | 2024-07-24 |
| Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy Entospletinib, Rituximab, Cyclophosphamide - DLBCL | Phase 1 / Phase 2 | Terminated | The Lymphoma Academic Research Organisation | 25 | 2017-07-26 | 2020-09-02 |
| A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies acalabrutinib, vistusertib - DLBCL, Richter Syndrome | Phase 1 / Phase 2 | Terminated | Acerta Pharma BV | 25 | 2017-06-29 | 2021-01-06 |
| Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas 90Y-DOTATOC - DLBCL, MCL | Phase 2 | Terminated | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1 | 2016-12-22 | 2018-03-19 |
Lymphoma, Mantle-Cell (2) · Recurrence (2) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1) · Neurotoxicity Syndromes (1)
Disease Attributes (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Chemically-Induced Disorders (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Nervous System Diseases (1)
6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · 90Y-octreotide, DOTA-Tyr(3)- (1) · Cyclophosphamide (1) · Doxorubicin (1) · Prednisone (1) · Rituximab (1) · Vincristine (1) · acalabrutinib (1) · defibrotide (1) · vistusertib (1)
Acerta Pharma BV (1) · IGM Biosciences, Inc. (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Jazz Pharmaceuticals (1) · The Lymphoma Academic Research Organisation (1)
United States (3) · France (2) · Italy (2) · Australia (1) · Belgium (1) · Czechia (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Emmanuelle Tchernonog (1) · Gilles Salles (1) · Julien Depaus (1) · Maddalena Sansovini, MD (1)